article

Upstream Bioprocessing In-Depth Focus 2020

Posted: 27 November 2020 | | No comments yet

In the upstream bioprocessing in-depth focus experts reveal how CRISPR is being leveraged to enhance productivity in cell line development and why industry is focusing on producing animal-component free glycosaminoglycans.

Upstream Bioprocessing IDF











    To read this in-depth focus in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Eppendorf

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Articles in this in-depth focus:

    • Advancing CHO cell line engineering with CRISPR
      Chinese hamster ovary (CHO) cell lines are a firm favourite with biologics companies because of the extensive developmental work undertaken in recent decades. In this article, Junrui Li divulges how CRISPR technology is now being employed to further enhance productivity.
    • Biosynthetic polysaccharidebased drugs and nutraceuticals from non-animal sources
      Glycosaminoglycans (GAGs) are a class of naturally occurring polysaccharides that play vital roles in cellular functions. GAGs (eg, hyaluronic acid, heparosan, chondroitin, chondroitin sulfate, heparan sulfate and heparin) have also been utilised in biopharmaceutical and nutraceutical industries. Animal-sourced GAGs can contain process impurities and contaminants, which may result in adverse effects. To overcome this issue, efforts have focused on the industrial production of animal-component free GAGs. This review focuses on the production of tailored biosynthetic GAGs that have specific and novel functions, including biosynthetic heparins, potential anti-viral and drug delivery applications.
    Send this to a friend